Neoadjuvant S-1 and oxaliplatin plus bevacizumab therapy for high-risk locally advanced rectal cancer: A prospective multicenter phase II study.
Takuya MiuraHajime MorohashiYoshiyuki SakamotoTakuji KagiyaTatsuya HasebeYoshihito NakayamaHiromasa FujitaKenichi HakamadaPublished in: Annals of gastroenterological surgery (2023)
NAC yielded a clinically significant effect in about half of high-risk LARC patients. If NAC alone is ineffective, radiotherapy should be added, even if extended surgery is intended.
Keyphrases
- locally advanced
- rectal cancer
- phase ii study
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- transcription factor
- minimally invasive
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- randomized controlled trial
- early stage
- prognostic factors
- patient reported outcomes
- open label
- clinical trial
- lymph node
- cross sectional
- acute coronary syndrome
- radiation induced
- metastatic colorectal cancer
- atrial fibrillation